Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to find how Elevance Health’s medical loss ratio or Medicaid membership changed quarter-by-quarter? The company’s disclosures run hundreds of pages and detail complex Blue Cross Blue Shield licensing, state risk corridors, and pharmacy benefit trends. Elevance Health SEC filings explained simply can save professionals hours—especially when you need Elevance Health insider trading Form 4 transactions right before an earnings call.
Stock Titan’s platform delivers just that. Our AI reads every Elevance Health quarterly earnings report 10-Q filing, flags deviations, and produces concise narratives. Need Elevance Health Form 4 insider transactions real-time? You’ll get alerts within seconds. Each document page is paired with a side-by-side Elevance Health earnings report filing analysis, making understanding Elevance Health SEC documents with AI straightforward. We also surface:
- Elevance Health annual report 10-K simplified into key metrics
- Elevance Health proxy statement executive compensation distilled to pay-for-performance tables
- Elevance Health 8-K material events explained so you grasp market-moving news instantly
Whether you track Commercial & Specialty Business growth, scrutinize Government Business risk, or monitor Elevance Health executive stock transactions Form 4 for sentiment shifts, our coverage stays current with EDGAR in real time. Investors use these insights to compare segment margins, watch medical loss ratios, and anticipate regulatory impacts—without wading through dense accounting language. Access every filing, AI summary, and historical trend in one place, and make faster, better-informed decisions.
Elevance Health, Inc. reported that its Board of Directors elected Amy W. Schulman as an independent director on December 10, 2025. Her service will begin on January 12, 2026 and her term will run until the company’s 2028 annual meeting of shareholders. The Board also appointed her to the Audit Committee and the Finance Committee.
The Board determined that Ms. Schulman is an independent director under NYSE listing standards and the company’s own independence guidelines, and that she qualifies as an “audit committee financial expert” under SEC regulations. She will be compensated under Elevance Health’s standard non-employee director compensation program, and the company issued a press release about her election, which is included as an exhibit.
Elevance Health, Inc. (ELV)3,341 shares of common stock, held directly. A portion of this amount represents restricted share units that vest on varying dates between February 1, 2026 and March 3, 2028. This update is administrative in nature and aligns the reported ownership with the accurate share count.
Elevance Health (ELV) reaffirmed its full‑year 2025 guidance. Management continues to expect shareholders’ earnings of approximately $24.70 per diluted share, which includes about $5.30 per diluted share of net unfavorable items. Excluding these items, adjusted shareholders’ earnings are still expected to be approximately $30.00 per diluted share.
The company also reaffirmed its full‑year 2025 benefit expense ratio guidance of approximately 90.0%. These expectations reflect current views on market conditions, operations, policy, and cost trends, and actual results could differ if assumptions change.
Elevance Health (ELV) reported stronger Q3 2025 results. Total revenues were $50.711 billion versus $45.106 billion a year ago, driven by premiums of $41.791 billion (up from $36.809 billion), product revenue of $6.159 billion, and service fees of $2.137 billion. Shareholders’ net income rose to $1.189 billion from $1.016 billion, and diluted EPS increased to $5.32 from $4.36.
For the first nine months, total revenues reached $149.378 billion versus $131.569 billion, while shareholders’ net income was $5.115 billion versus $5.562 billion. Operating cash flow was $4.206 billion versus $5.102 billion.
On the balance sheet, cash and cash equivalents were $8.713 billion, total assets $122.749 billion, and total shareholders’ equity improved to $43.953 billion with accumulated other comprehensive loss narrowing to $(543) million from $(1,147) million. Long-term debt rose to $31.173 billion. The company repurchased $2.134 billion of common stock year-to-date and paid $1.152 billion in dividends. Shares outstanding were 222,238,763 as of October 14, 2025.
Recent acquisitions of Centers and CareBridge were integrated; purchase accounting remains open, with associated goodwill and intangibles recorded.
Elevance Health, Inc. furnished an update on its business by issuing a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 21, 2025.
The company stated that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not incorporated by reference into Securities Act filings unless specifically referenced.
Mark Kaye, EVP & CFO of Elevance Health, Inc. (ELV), reported a sale of 2,895 shares of common stock on 10/02/2025 at a price of $340.24 per share. The filing states this disposition was a payment of tax liability by withholding stock related to the vesting of previously granted restricted stock. After the transaction, the reporting person beneficially owned 16,082 shares directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Erin M. Wessling, EVP & Chief Legal Officer of Elevance Health, Inc. (ELV), reported a transaction on 09/03/2025 in which 152 shares of Common Stock were disposed at a price of $321.59 per share. The Form 4 shows 5,020 shares remained beneficially owned after the reported transaction, held directly. The filing identifies the transaction code F and includes an explanation that the disposition was the payment of a tax liability by withholding stock incident to the vesting of previously granted restricted stock. The form was signed on behalf of the reporting person by Kathleen S. Kiefer on 09/05/2025.
Elevance Health director and EVP & Chief Legal Officer Erin M. Wessling filed an initial Form 3 disclosing direct beneficial ownership of 4,241 shares of common stock (restricted share units vesting 9/3/2025–3/3/2028) and two employee stock options covering 394 shares (exercise price $562.29) and 1,922 shares (exercise price $395.50). The filing notes a paper Form 3 was delivered 08/21/2025 because the reporting person's Form ID was pending.
Craig R. Ryan, Executive Vice President and Chief HR Officer of Elevance Health, Inc. (ELV), disclosed initial beneficial ownership in a Form 3 filed for the 08/11/2025 event date. He directly owns 4,383 shares of common stock, including 3,341 restricted stock units that vest between 02/01/2026 and 03/03/2028. He also holds two employee stock options: one for 965 shares exercisable beginning 03/01/2025 at $499.11 and one for 1,201 shares exercisable beginning 03/03/2026 at $395.50, both vesting in annual installments. The paper Form 3 was delivered 08/21/2025 due to a pending Form ID; an electronic filing followed when EDGAR access was available.
FAQ
What is the current stock price of Elevance Health (ELV)?
What is the market cap of Elevance Health (ELV)?
